^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
NK/γδ T cell-enriched cell therapy
i
Other names: NK/γδ T cell-enriched cell therapy, allogeneic transplant donor lymphocytes depleted of TCR-αβ T cells & B cells and enriched for NK cells & TCRγδ T cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Case Comprehensive Cancer Center
Drug class:
NK cell stimulant, γδ TCR modulator
Related drugs:
over1year
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT (clinicaltrials.gov)
P1, N=10, Not yet recruiting, Leland Metheny | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Nov 2022 --> Nov 2023
Trial completion date • Trial primary completion date
|
NK/γδ T cell-enriched cell therapy
Share via
